肠道微生物群介导着血糖胺减弱与糖尿病相关的认知衰退
Liqin Qi1, Huimin Kang2, Feihui Zeng1
1Department of Endocrinology, Fujian Institute of Endocrinology, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China.
概括
塞马格卢提德治疗通过保护大脑细胞和改变肠道细菌,改善了糖尿病小鼠的认知功能. 这表明药物之间存在联系.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 微生物组研究 微生物组研究
背景情况:
- 糖尿病相关认知衰退 (DACD) 是糖尿病 (DM) 的严重并发症.
- 作为GLP-1受体激动剂的塞马格卢提德,表现出神经营养和神经保护作用.
- 在DACD患者中,塞马格卢提德的确切机制尚未完全理解.
研究的目的:
- 在小鼠模型中调查赛马格卢提德改善DACD的疗效.
- 阐明潜在的机制,包括对大脑,肠道微生物群和代谢物的影响.
主要方法:
- 通过使用高脂肪饮食和 estreptozotocin 建立了一种因糖尿病引起的认知衰退的小鼠模型.
- 小鼠接受了12周的塞马格卢提德 (30nmol/kg qd) 治疗.
- 分析包括认知测试,组织学检查,肠道微生物群分析,代谢学和转录学.
主要成果:
- 塞马格卢提德显著改善了认知功能,并减少了海马神经元损失和神经炎症.
- 治疗改变了肠道微生物群的组成,增加了像Bacteroides这样的有益细菌,并减少了其他细菌.
- 观察到便/血清代谢物和大脑转录组的变化,神经活性连接体-受体相互作用的丰富.
结论:
- 塞马格卢提德在小鼠中表现出对糖尿病相关认知能力下降的保护作用.
- 这些好处与肠道微生物群和微生物群-肠道-大脑轴的调节有关.
- 这些发现突显了塞马格卢提德在治疗糖尿病认知障碍方面的潜在治疗作用.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
598
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
598
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
526
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
526
01:24Glucagon-like Receptor Agonists
854
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
854
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
588
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
588
01:19Psychoneuroimmunology: Diabetes and Cancer
462
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
462
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
495
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
495